Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition September 22, 2026Posted inBiotechnology Celldex touted a double phase 3 trial win in patients with treatment-refractory chronic spontaneous urticaria. Post navigation Previous Post Amgen’s Horizon-acquired fusion protein eases Sjögren’s severity in ph. 3 winNext PostNovartis secures new radioligand in $900M deal as competition strengthens
